Notice of Proposed Sale · 144
Revolution Medicines, Inc.
RVMDNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Revolution Medicines, Inc.
- Issuer CIK
- 0001628171
- SEC file number
- 001-39219
- Phone
- 6504816801
- Person for whose account securities are to be sold
- ANTHONY MANCINI
- Relationships to issuer
- Officer
- Street
- 700 Saginaw Drive
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94063
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 1,764 | 347,402.16 | 214,336,418 | 09/18/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 09/15/2026 | Restricted Stock Units | Issuer | 1,764 | N | 09/15/2026 | N/A |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| ANTHONY MANCINI | Common | 09/15/2026 | 1,774 | 353,449.03 |
| 10b5-1 Sales for ANTHONY MANCINI | Common | 09/10/2026 | 15,448 | 3,153,807.11 |
Seller — prior-sale row 1, entry 1
- Name
- ANTHONY MANCINI
- Street
- 700 Saginaw Drive
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94063
Seller — prior-sale row 2, entry 1
- Name
- 10b5-1 Sales for ANTHONY MANCINI
- Street
- 700 Saginaw Drive
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94063
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 09/18/2026
- Signed
- /s/ Anthony Mancini
- Plan adoption dates
- 06/11/2026
Company context
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. These product candidates are investigational and have not been approved for commercial use in any indication. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.